These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 7589641)

  • 41. Effects of progestogen on lipids, lipoproteins and apolipoproteins during transdermal estrogen replacement therapy with and without medroxyprogesterone acetate.
    Castelo-Branco C; Casals E; Sanllehy C; Duran M; Fortuny A; Vanrell JA
    J Reprod Med; 1996 Nov; 41(11):833-8. PubMed ID: 8951134
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term effects of transdermal estradiol with and without medroxyprogesterone acetate.
    Pang SC; Greendale GA; Cedars MI; Gambone JC; Lozano K; Eggena P; Judd HL
    Fertil Steril; 1993 Jan; 59(1):76-82. PubMed ID: 8419226
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Coadministration of nomegestrol acetate does not diminish the beneficial effects of estradiol on coronary artery dilator responses in nonhuman primates (Macaca fascicularis).
    Williams JK; Cline JM; Honoré EK; Delansorne R; Paris J
    Am J Obstet Gynecol; 1998 Nov; 179(5):1288-94. PubMed ID: 9822518
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Continuous hormone replacement therapy for menopause combining nomegestrol acetate and gel, patch, or oral estrogen: a comparison of amenorrhea rates.
    Blanc B; Cravello L; Micheletti MC; d'Ercole C; Zartarian M
    Clin Ther; 1998; 20(5):901-12. PubMed ID: 9829442
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment-induced cyclic variations in serum lipids, lipoproteins, and apolipoproteins after 2 years of combined hormone replacement therapy: exaggerated cyclic variations in smokers.
    Haarbo J; Christiansen C
    Obstet Gynecol; 1992 Oct; 80(4):639-44. PubMed ID: 1407887
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Biological and clinical safety of nomegestrol acetate administered alone then associated in inverse sequence with transdermal 17 beta estradiol, in women at risk of dyslipoproteinemia type IIa].
    Zartarian M; Chevallier T; Micheletti MC; Leber C; Jamin C
    Ann Endocrinol (Paris); 1998 Dec; 59(5):411-6. PubMed ID: 9949893
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Cardiovascular and metabolic effects of medroxyprogesterone acetate versus conjugated equine estrogen after premenopausal hysterectomy with bilateral ovariectomy.
    Kalyan S; Hitchcock CL; Sirrs S; Pudek M; Prior JC
    Pharmacotherapy; 2010 May; 30(5):442-52. PubMed ID: 20411996
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Assessment of the metabolic tolerance in postmenopausal women over a 1-year period of two hormone replacement therapies containing estradiol in combination with either norgestrel or trimegestone.
    Meuwissen JH; Beijers-De Bie L; Vihtamaki T; Tuimala R; Siseles N; Magaril C; The HS; Houben PW; Murga M; Spielmann D; De Villiers TJ
    Gynecol Endocrinol; 2002 Apr; 16(2):155-62. PubMed ID: 12012627
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Hormone replacement therapy, hormone levels, and lipoprotein cholesterol concentrations in elderly women.
    Paganini-Hill A; Dworsky R; Krauss RM
    Am J Obstet Gynecol; 1996 Mar; 174(3):897-902. PubMed ID: 8633665
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oral contraceptive and postmenopausal estrogen effects on lipoprotein triglyceride and cholesterol in an adult female population: relationships to estrogen and progestin potency.
    Knopp RH; Walden CE; Wahl PW; Hoover JJ; Warnick GR; Albers JJ; Ogilvie JT; Hazzard WR
    J Clin Endocrinol Metab; 1981 Dec; 53(6):1123-32. PubMed ID: 7298796
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The menopause and hormone replacement therapy: lipids, lipoproteins, coagulation and fibrinolytic factors.
    Tikkanen MJ
    Maturitas; 1996 Mar; 23(2):209-16. PubMed ID: 8735358
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Estrogen, progestogens and cardiovascular risk.
    Stefanick ML
    J Reprod Med; 1999 Feb; 44(2 Suppl):221-6. PubMed ID: 11392036
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol.
    Wahl P; Walden C; Knopp R; Hoover J; Wallace R; Heiss G; Rifkind B
    N Engl J Med; 1983 Apr; 308(15):862-7. PubMed ID: 6572785
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions.
    Espeland MA; Marcovina SM; Miller V; Wood PD; Wasilauskas C; Sherwin R; Schrott H; Bush TL
    Circulation; 1998 Mar; 97(10):979-86. PubMed ID: 9529266
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17 beta-oestradiol on ovarian function in comparison to a monophasic combined oral contraceptive containing drospirenone and ethinylestradiol.
    Duijkers IJ; Klipping C; Grob P; Korver T
    Eur J Contracept Reprod Health Care; 2010 Oct; 15(5):314-25. PubMed ID: 20695770
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lipid changes after hormone replacement therapy for menopause.
    Kable WT; Gallagher JC; Nachtigall L; Goldgar D
    J Reprod Med; 1990 May; 35(5):512-8. PubMed ID: 2112606
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects on serum lipid profiles of continuous 17beta-estradiol, intermittent norgestimate regimens versus continuous combined 17beta-estradiol/norethisterone acetate hormone replacement therapy.
    Ylikorkala O; Lim P; Caubel P
    Clin Ther; 2000 May; 22(5):622-36. PubMed ID: 10868559
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Evaluation of the climacteric symptomatology modifications and clinical-instrumental parameters in women in physiological menopause treated with hormone replacement therapy with nomegestrol acetate and in surgical menopause treated with estrogen replacement therapy. Part I].
    Savoca S; D'Agosta S; Lombardo G
    Minerva Ginecol; 2007 Jun; 59(3):205-14. PubMed ID: 17576399
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of oral and transdermal hormone replacement therapy on lipid profile and Lp(a) level in menopausal women with hypercholesterolemia.
    Perrone G; Stefanutti C; Galoppi P; Anelli G; Capri O; Lucani G; Vivenzio A; Mazzarella B; Zichella L
    Int J Fertil Menopausal Stud; 1996; 41(6):509-15. PubMed ID: 9010744
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of hormone replacement therapy on cardiovascular risk factors in postmenopausal women.
    Chen FP; Lee N; Wang CH; Cherng WJ; Soong YK
    Fertil Steril; 1998 Feb; 69(2):267-73. PubMed ID: 9496340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.